Shao Jiasheng, Fan Rong, Hu Jianrong, Zhang Tiejun, Lee Catherine, Huang Xuyuan, Wang Fei, Liang Haiying, Jin Ye, Jiang Ying, Gu Yanhua, Huang Gang
Department of Infectious Diseases and Immunology, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai 201899, China.
Genomics, Biotechnology Center, Center for Molecular and Cellular Bioengineering, Technische Universität, 01307 Dresden, Germany.
Vaccines (Basel). 2022 Aug 28;10(9):1409. doi: 10.3390/vaccines10091409.
Studies on the Omicron variant infection have generally been restricted to descriptions of its initial clinical and epidemiological characteristics. We investigated the timeline-related progression and clinical outcome in hospitalized individuals with the Omicron variant.
We conducted a retrospective, single-centered study including 226 laboratory-confirmed cases with the Omicron variant between 6 April and 11 May 2022 in Shanghai, China. The final date of follow-up was 30 May 2022.
Among 226 enrolled patients, the median age was 52 years, and 118 (52.2%) were female. The duration from onset of symptoms to hospitalization was 3 days (interquartile range (IQR): 2-4 days) for symptomatic patients. Cough occurred in 168 patients (74.3%). The median interval to negative reverse-transcriptase PCR tests of nasopharynx swab was 10 days ((IQR): 8-13 days). No radiographic progressions were found in 196 patients on the 7th day after onset of symptoms. The median duration of fever in all participants was 5 days (IQR: 4-6 days). The median PCR conversion time of Paxlovid-treated patients was 8 days (IQR: 7-10 days) compared with that of a traditional Chinese herb medicine lianhuaqingwen (10 days, IQR: 8-13 days) ( = 0.00056). Booster vaccination can significantly decrease the severity of Omicron infection when compared with unvaccinated patients ( = 0.009). In multivariate logistic analysis, erythrocyte sedimentation rate (ESR) (OR = 1.05) was independently related to the severity of the infection.
The majority of clinical symptoms of Omicron infection were not severe. Early and aggressive administration of Paxlovid can significantly reduce the PCR conversion time. Booster vaccination should also be highly recommended in the population over 14 years old.
关于奥密克戎变异株感染的研究通常局限于对其初始临床和流行病学特征的描述。我们调查了感染奥密克戎变异株的住院患者与时间线相关的病情进展和临床结局。
我们进行了一项回顾性单中心研究，纳入了2022年4月6日至5月11日期间在中国上海的226例实验室确诊的奥密克戎变异株感染病例。随访的最后日期为2022年5月30日。
在226例入组患者中，中位年龄为52岁，118例（52.2%）为女性。有症状患者从症状出现到住院的时间为3天（四分位间距（IQR）：2 - 4天）。168例患者（74.3%）出现咳嗽。鼻咽拭子逆转录聚合酶链反应（RT-PCR）检测结果转为阴性的中位间隔时间为10天（IQR：8 - 13天）。196例患者在症状出现后第7天未发现影像学进展。所有参与者发热的中位持续时间为5天（IQR：4 - 6天）。与服用传统中药连花清瘟的患者相比，服用帕罗韦德的患者PCR转阴时间的中位值为8天（IQR：7 - 10天），而服用连花清瘟的患者为10天（IQR：8 - 13天）（P = 0.00056）。与未接种疫苗的患者相比，加强接种疫苗可显著降低奥密克戎感染的严重程度（P = 0.009）。在多因素逻辑回归分析中，红细胞沉降率（ESR）（比值比（OR） = 1.05）与感染的严重程度独立相关。
奥密克戎感染的大多数临床症状并不严重。早期积极使用帕罗韦德可显著缩短PCR转阴时间。对于14岁以上人群，也应强烈推荐加强接种疫苗。
